In last trading session, C4 Therapeutics Inc (NASDAQ:CCCC) saw 1.34 million shares changing hands with its beta currently measuring 2.96. Company’s recent per share price level of $2.99 trading at -$0.02 or -0.66% at ring of the bell on the day assigns it a market valuation of $211.06M. That closing price of CCCC’s stock is at a discount of -297.32% from its 52-week high price of $11.88 and is indicating a premium of 4.01% from its 52-week low price of $2.87.
For C4 Therapeutics Inc (CCCC), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.80. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.45 in the current quarter.
C4 Therapeutics Inc (NASDAQ:CCCC) trade information
Upright in the red during last session for losing -0.66%, in the last five days CCCC remained trading in the red while hitting it’s week-highest on Thursday, 02/13/25 when the stock touched $2.99 price level, adding 11.54% to its value on the day. C4 Therapeutics Inc’s shares saw a change of -16.94% in year-to-date performance and have moved -9.39% in past 5-day. C4 Therapeutics Inc (NASDAQ:CCCC) showed a performance of -22.34% in past 30-days.
Wall Street analysts have assigned a consensus price target of 16 to the stock, which implies a rise of 81.31% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 20. It follows that stock’s current price would drop -301.34% in reaching the projected high whereas dropping to the targeted low would mean a loss of -301.34% for stock’s current value.
C4 Therapeutics Inc (CCCC) estimates and forecasts
This year revenue growth is estimated to rise 72.35% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 4.43M for the same. And 3 analysts are in estimates of company making revenue of 3.33M in the next quarter. Company posted 3.26M and 3.04M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -36.05% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 44.17% while estimates for its earnings growth in next 5 years are of 12.86%.
C4 Therapeutics Inc (NASDAQ:CCCC)’s Major holders
LYNX1 CAPITAL MANAGEMENT LP is the top institutional holder at CCCC for having 6.88 million shares of worth $31.79 million. And as of 2024-06-30, it was holding 9.9993 of the company’s outstanding shares.
The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 4.88 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.0891 of outstanding shares, having a total worth of $22.54 million.
